医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharm-Olam Continues Global Expansion; Adds Full-Service Coverage in Asia-Pacific Region

2016年01月13日 AM01:47
このエントリーをはてなブックマークに追加


 

HOUSTON

Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is proud to announce its expansion of Phase I-IV clinical trial services into the Asia-Pacific region.

This expansion includes the opening of legal entities in Vietnam, Philippines, South Korea, Malaysia, Thailand and Taiwan.

“In response to requests coming in from our clients, we have begun expanding our services into the Asia-Pacific region,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer (USA). He continued, “We anticipate significant study growth in the region over the next few years, and we are now poised to guide our clients in the development process in these promising yet often overlooked markets.”

Suri added, “The successes we’ve shared have been a result of offering our clients solutions for their unique needs. Our Asia-Pacific expansion efforts will allow us to offer comprehensive and flexible solutions in a timely and efficient manner. We look forward to continuing to support our clients globally.”

For more information about Pharm-Olam and its global Phase I-IV clinical research solutions, contact info@pharm-olam.com.

About Pharm-Olam International Group

Pharm-Olam International is a multi-national Contract Research Organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160112006251/en/

CONTACT

Pharm-Olam International
Mark Eberhardt, +1-713-599-7350

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024